KEYNOTE-010: Durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab

Autores: Herbst, R.; Garon, E.; Kim, D. W.; Cho, B. C. ; Gadgeel, S.; Lena, H.; Gurpide Ayarra, Luis Alfonso; Han, J. Y.; Arvis, C. D.; Majem, M. ; Forster, M.; Monnet, I.; Novella, S.; Saka, H. ; Szalai, Z.; Gubens, M.; Su, W. C.; Lubiniecki, G. ; Shentu, Y. ; Ferraro, G. ; Baas, P.